| Designing and producing modified, new-to-nature peptides with antimicrobial activity by use of a combination of various lantibiotic modification enzymes AJ van Heel, D Mu, M Montalbán-López, D Hendriks, OP Kuipers ACS synthetic biology 2 (7), 397-404, 2013 | 105 | 2013 |
| Discovery, production and modification of five novel lantibiotics using the promiscuous nisin modification machinery AJ van Heel, TG Kloosterman, M Montalban-Lopez, J Deng, A Plat, ... ACS synthetic biology 5 (10), 1146-1154, 2016 | 94 | 2016 |
| Antibody-based cancer therapy: successful agents and novel approaches D Hendriks, G Choi, M de Bruyn, VR Wiersma, E Bremer International review of cell and molecular biology 331, 289-383, 2017 | 62 | 2017 |
| A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint I Koopmans, D Hendriks, DF Samplonius, RJ van Ginkel, S Heskamp, ... Oncoimmunology 7 (8), e1466016, 2018 | 54 | 2018 |
| Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction D Hendriks, Y He, I Koopmans, VR Wiersma, RJ van Ginkel, ... Oncoimmunology 5 (8), e1202390, 2016 | 49 | 2016 |
| Hairy cell leukemia cell lines expressing annexin A1 and displaying B-cell receptor signals characteristic of primary tumor cells lack the signature BRAF mutation to reveal … NJ Weston-Bell, D Hendriks, G Sugiyarto, NA Bos, HC Kluin-Nelemans, ... Leukemia 27 (1), 241-245, 2013 | 33 | 2013 |
| C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity VR Wiersma, M de Bruyn, C Shi, MJM Gooden, MCA Wouters, ... MAbs 7 (2), 321-330, 2015 | 30 | 2015 |
| Melanoma-directed activation of apoptosis using a novel bispecific antibody directed at MCSP and TRAIL receptor 2/Death Receptor 5 Y He, D Hendriks, R van Ginkel, D Samplonius, E Bremer, W Helfrich Journal of Investigative Dermatology 136, 541-4, 2016 | 28 | 2016 |
| Hairy cell leukemia cell lines display B-cell receptor signals characteristic of primary tumor cells but lack the signature BRAF mutation to reveal unrepresentative origins N Weston-Bell, D Hendriks, G Sugiyarto, N Bos, J Kluin-Nelemans, ... HAEMATOLOGICA 97, 124-124, 2012 | 1 | 2012 |
| Novel antibody-based drugs for PD-L1 and TRAIL-R targeted cancer immunotherapy D Hendriks | | 2017 |
| First and shared f irst author publications AJ van Heel, T Kloosterman, M Montalbán-López, D Jingjing, A Plat, ... Prediction, production and characterization of post-translationally modified …, 2016 | | 2016 |
| Melanoma-directed activation of apoptosis using a novel bispecific antibody directed against MCSP and Death Receptor 5 Y He, D Hendriks, R Van Ginkel, D Samplonius, E Bremer, W Helfrich European Journal of Cancer 1 (61), S119, 2016 | | 2016 |
| A novel bispecific antibody for EGFR-directed PD-1/PD-L1 immune checkpoint inhibition I Koopmans, D Hendriks, DF Samplonius, E Bremer, W Helfrich | | |
Prof. dr. Wijnand HelfrichUniversity Medical Center GroningenDirección de correo verificada de umcg.nl
